

SMITH & NEPHEW PLC

11 July 2025

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
 MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

This announcement is made in accordance with the UK Market Abuse Regulation (Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018).

On 10 July 2025, Smith & Nephew plc (the "Company") received notification of the following transactions as detailed below.

Reason for the notification	
Initial notification /Amendment	Initial notification
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
Name	Smith & Nephew plc
LEI	213800ZTMDN8S67S1H61
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
Description of the financial instrument, type of instrument	Smith & Nephew plc SPON ADR American Depository Shares (ADS)
Identification code	ISIN: US83175M2052
Nature of the transaction	Purchase of American Depository Shares as participants of the Company's Employee Stock Purchase Plan
Date of Transaction	2025-07-09
Place of Transaction	New York Stock Exchange

Name	Director / PDMR	Price ()	Volume	Aggregated information
Deepak Nath (Chief Executive Officer)	Director	29.77358	512.29508	N/A Single Transaction
Paul Connolly (President, Global Operations)	PDMR	29.77358	512.29508	N/A Single Transaction
Craig Gaffin (President, Orthopaedics)	PDMR	29.77358	381.29219	N/A Single Transaction
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer)	PDMR	29.77358	114.62247	N/A Single Transaction
Scott Schaffner (President, Sports Medicine)	PDMR	29.77358	298.19045	N/A Single Transaction

Philip Horner
 Deputy Company Secretary
 Smith & Nephew plc

SMITH & NEPHEW PIC

Tel: +44 (0)1923 477100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFIFETDDILLIE